dc.contributor | Villareal Trujillo, Nicolás | |
dc.contributor | Camacho López, Paul Anthony | |
dc.contributor | Villareal Trujillo, Nicolás [0001691724] | |
dc.contributor | Camacho López, Paul Anthony [0000323578] | |
dc.contributor | Mantilla Rey, Daniel José [D6tAXGsAAAAJ&hl=es&oi=sra] | |
dc.contributor | Camacho López, Paul Anthony [-u8d7_QAAAAJ] | |
dc.contributor | Camacho López, Paul Anthony [0000-0002-6233-9582] | |
dc.creator | Mantilla Rey, Daniel José | |
dc.date.accessioned | 2022-08-01T19:37:24Z | |
dc.date.accessioned | 2023-06-12T20:43:07Z | |
dc.date.available | 2022-08-01T19:37:24Z | |
dc.date.available | 2023-06-12T20:43:07Z | |
dc.date.created | 2022-08-01T19:37:24Z | |
dc.date.issued | 2019 | |
dc.identifier | http://hdl.handle.net/20.500.12749/17173 | |
dc.identifier | instname:Universidad Autónoma de Bucaramanga - UNAB | |
dc.identifier | reponame:Repositorio Institucional UNAB | |
dc.identifier | repourl:https://repository.unab.edu.co | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/6663877 | |
dc.description.abstract | El cáncer de próstata es una de las patologías oncológicas con mayor incidencia y prevalencia a nivel mundial. Dentro de las opciones terapéuticas, la prostatectomía radical ha logrado aumentar la supervivencia global y cáncer específica, así como disminuir la mortalidad global en los pacientes con cáncer de próstata localizado. A pesar de los buenos resultados oncológicos logrados con este procedimiento, múltiples estudios han mostrado diversas tasas de progresión bioquímica de la enfermedad las cuales pueden variar desde un 15 a 60%. La radioterapia de salvamento posterior a la prostatectomía radical es la opción de tratamiento mas frecuentemente utilizada, con el fin de controlar la enfermedad, sin embargo aún no esta claro el verdadero alcance, y las características optimas del paciente y la enfermedad para maximizar sus resultados, lo que requiere realizar más estudios. Basados en esto se hace necesario realizar un estudio para evaluar el uso de esta técnica en nuestra institución y poder evaluar los resultados obtenidos en nuestra población. | |
dc.language | spa | |
dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
dc.publisher | Facultad Ciencias de la Salud | |
dc.publisher | Especialización en Urología | |
dc.relation | [1] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. | |
dc.relation | [2] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. | |
dc.relation | 3] Li C, Ekwueme DU. Years of potential life lost caused by prostate cancer deaths in the United States-Projection from 2004 through 2050. Cancer Epidemiol. 2010;34(4):368-72. | |
dc.relation | [4] Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Bogotá: Instituto Nacional de Cancerología. 2015. | |
dc.relation | [5] Claudia U, Sonia O, Herrera V. Incidencia y mortalidad por cáncer en el área metropolitana de Bucaramanga 2003-2007. Colombia Médica. 2012;43(4):290-7 | |
dc.relation | [6] Bill-axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-42. | |
dc.relation | [7] Meltzer D, Egleston B, Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health. 2001;91(1):126-8. | |
dc.relation | [8] Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910-4. | |
dc.relation | [9] Kane CJ, Im R, Amling CL, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3):695-700. | |
dc.relation | [10] Pound CR, Partin AW, Eisenberger MA, et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. JAMA Otolaryngol Head Neck Surg. 2015;141(5):428. | |
dc.relation | [11] Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171(4):1393-401. | |
dc.relation | [12] Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163(6):1632-42. | |
dc.relation | [13] Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59(6):893-9. | |
dc.relation | 14] Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035-41. | |
dc.relation | [15] Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65(6):1034-43. | |
dc.relation | [16] Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy - what is the best time to treat?. Radiother Oncol. 2012;103(2):239-43. | |
dc.relation | [17] Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer. 2012;48(6):837-44. | |
dc.relation | [18] Stephenson AJ, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein E a, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. 2012;291(11):1325–32. | |
dc.relation | [19] Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–54. | |
dc.relation | [20] King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104-11. | |
dc.relation | [21] Taguchi S, Shiraishi K, Fukuhara H, et al. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?. Radiat Oncol. 2016;11:102. | |
dc.relation | [22] Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760-9. | |
dc.relation | [23] Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol [Internet]. 2016;69(4):728–33. | |
dc.relation | [24] Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, et al. Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring System. J Urol. 2006;176(3):985–90. | |
dc.relation | 25] Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28. | |
dc.relation | [26] Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–56. | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.rights | Abierto (Texto Completo) | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Atribución-NoComercial-SinDerivadas 2.5 Colombia | |
dc.title | Relación entre el valor del antígeno prostático específico al momento de iniciar radioterapia de salvamento posterior a prostatectomía radical y la progresión a recaída bioquímica en pacientes con cáncer de próstata | |